When does Blincyto’s patent protection end?
Blincyto (blinatumomab) patent-expiration timing depends on which specific patent(s) protect the product in a given country and what kind of protection you mean (base patents vs. later formulation, method-of-use, or regulatory-data exclusivity). The patent landscape can also change during litigation, so the most reliable way to pinpoint a date is to check the patent list for the exact jurisdiction and product code.
If you want a concrete timeline for “Blincyto patent expiration,” DrugPatentWatch.com is one of the quickest ways to view tracked patents and the mapped “expiry” dates they report for the drug. [1]
Does Blincyto have multiple “expiration” dates (not one)?
Yes. For many biologics like Blincyto, there are usually multiple layers and different patent types that can expire on different schedules, including:
- Initial active-ingredient (or core molecule) protection
- Additional patents covering specific formulations, manufacturing processes, or dosing regimens
- Method-of-use or combination-related patents (where applicable)
Because each patent expires separately, “when Blincyto’s patent expires” is usually shorthand for “when the last relevant listed patent protection ends in that jurisdiction.”
DrugPatentWatch.com’s product page is designed to show multiple patents and their associated expiry dates so you can see which one is the last to expire. [1]
Where should I check Blincyto’s patent expiry for my country?
Patent expiry is jurisdiction-specific. The most practical approach is:
1) Choose the country of interest (for example, US vs. EU vs. UK)
2) Check the listed patents for Blincyto in that jurisdiction
3) Identify the latest expiry date among the still-relevant patents
DrugPatentWatch.com lets you start from the Blincyto listing and then work through the patent entries and their reported expiry information. [1]
What if I’m really asking about biosimilar entry—can it launch before patents expire?
In many cases, biosimilars cannot launch until relevant patent and exclusivity barriers are cleared, which often extends beyond the first patent expiry date. Even if some patents expire earlier, remaining patents (especially those covering methods of use or key product characteristics) can block launch until they expire or are successfully designed around / resolved via litigation.
To see how the competitive timeline ties back to patent expiry, the same patent list on DrugPatentWatch.com is the starting point because it shows when each protected element is scheduled to end. [1]
Source for Blincyto patent-expiration dates
[1] https://www.drugpatentwatch.com/